Financials data is unavailable for this security.
View more
Year on year KPC Pharmaceuticals Inc had revenues fall -6.99% from 8.28bn to 7.70bn, though the company grew net income 16.05% from 383.18m to 444.68m.
Gross margin | 41.97% |
---|---|
Net profit margin | 6.11% |
Operating margin | 7.61% |
Return on assets | 4.79% |
---|---|
Return on equity | 8.62% |
Return on investment | 8.10% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at KPC Pharmaceuticals Inc fell by 183.25m. However, the company earned 356.08m from its operations for a Cash Flow Margin of 4.62%. In addition the company used 339.22m on investing activities and also paid 201.84m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 7.10 |
---|---|
Tangible book value per share | 6.30 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.88 |
---|---|
Quick ratio | 1.44 |
Total debt/total equity | 0.2568 |
---|---|
Total debt/total capital | 0.199 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 15.69%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 1.81% |
---|---|
Div growth rate (5 year) | 14.87% |
Payout ratio (TTM) | 33.59% |
EPS growth(5 years) | 6.04 |
---|---|
EPS (TTM) vs TTM 1 year ago | 15.37 |
More ▼